DEXCOM INC (DXCM) Stock Price, Forecast & Analysis
NASDAQ:DXCM • US2521311074
DXCM Key Statistics, Chart & Performance
The current stock price of DXCM is 73.53 USD. In the past month the price decreased by -1.14%. In the past year, price decreased by -17.68%.
DXCM Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to DXCM. When comparing the yearly performance of all stocks, DXCM turns out to be only a medium performer in the overall market: it outperformed 42.34% of all stocks.
DXCM Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DXCM. DXCM has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
DXCM Financial Highlights
Over the last trailing twelve months DXCM reported a non-GAAP Earnings per Share(EPS) of 1.86. The EPS increased by 12.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.96% | ||
| ROA | 9.61% | ||
| ROE | 26.44% | ||
| Debt/Equity | 0.47 |
DXCM Forecast & Estimates
37 analysts have analysed DXCM and the average price target is 87.74 USD. This implies a price increase of 19.32% is expected in the next year compared to the current price of 73.53.
For the next year, analysts expect an EPS growth of 35.74% and a revenue growth 12.62% for DXCM
DXCM Ownership
DXCM Latest News, Press Relases and Analysis
DXCM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.68 | 195.119B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.09 | 179.003B | ||
| SYK | STRYKER CORP | 25.67 | 145.408B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.48 | 110.604B | ||
| BDX | BECTON DICKINSON AND CO | 11.74 | 52.82B | ||
| IDXX | IDEXX LABORATORIES INC | 42.59 | 50.758B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.23 | 46.296B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.75 | 38.388B | ||
| RMD | RESMED INC | 21.17 | 37.749B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DXCM
Company Profile
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Company Info
DEXCOM INC
6340 Sequence Drive
San Diego CALIFORNIA 92121 US
CEO: Kevin R. Sayer
Employees: 10250
Phone: 13026365400
DEXCOM INC / DXCM FAQ
Can you describe the business of DEXCOM INC?
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Can you provide the latest stock price for DEXCOM INC?
The current stock price of DXCM is 73.53 USD. The price increased by 0.62% in the last trading session.
What is the dividend status of DEXCOM INC?
DXCM does not pay a dividend.
What is the ChartMill rating of DEXCOM INC stock?
DXCM has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is DEXCOM INC (DXCM) stock traded?
DXCM stock is listed on the Nasdaq exchange.
Is DEXCOM INC (DXCM) expected to grow?
The Revenue of DEXCOM INC (DXCM) is expected to grow by 12.62% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for DEXCOM INC?
DEXCOM INC (DXCM) will report earnings on 2026-04-29.